Home/Pipeline/New Chemical Entities

New Chemical Entities

Undisclosed

DiscoveryResearch

Key Facts

Indication

Undisclosed

Phase

Discovery

Status

Research

Company

Faes Farma

About Faes Farma

Faes Farma is a leading Spanish pharmaceutical group with a mission to transform health through passion, science, and innovation, achieving €627 million in revenue in 2025 with 23% year-over-year growth. Its strategy is built on a vertically integrated model, a focus on key therapeutic molecules like Bilastine and Calcifediol, and strategic acquisitions to bolster international presence and leadership in ophthalmology. The company aims to be at the forefront of excellence in health and well-being, supported by a dual business model spanning human pharmaceuticals and animal nutrition.

View full company profile

Therapeutic Areas

Allergy Gastroenterology Ophthalmology Dermatology Cardiology Animal Nutrition

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active